Antibody–drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. From Wikipedia
The $100 million cGMP ADC facility in New York begins operations with a contract to produce a clinical-stage cancer therapy for an Asia-based biotech company.
